Photo from wikipedia
Autologous T cells engineered to target the MAGE-A4 cancer testis antigen successfully shrank a wide range of solid tumors with a manageable toxicity profile. In a phase I trial, the… Click to show full abstract
Autologous T cells engineered to target the MAGE-A4 cancer testis antigen successfully shrank a wide range of solid tumors with a manageable toxicity profile. In a phase I trial, the therapy, ADP-A2M4, showed the most promise in synovial sarcoma, yielding a disease control rate of around 90%.
Keywords:
targeting mage;
shrink tumors;
mage shrink;
mage;
cells targeting
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!